Microba Life Sciences Ltd (MAP) - Total Assets
Based on the latest financial reports, Microba Life Sciences Ltd (MAP) holds total assets worth AU$43.35 Million AUD (≈ $30.68 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Microba Life Sciences Ltd (MAP) shareholders funds for net asset value and shareholders' equity analysis.
Microba Life Sciences Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Microba Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data.
Microba Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Microba Life Sciences Ltd's total assets of AU$43.35 Million consist of 40.1% current assets and 59.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.71 Million | 24.8% |
| Accounts Receivable | AU$4.11 Million | 8.7% |
| Inventory | AU$1.94 Million | 4.1% |
| Property, Plant & Equipment | AU$3.87 Million | 8.2% |
| Intangible Assets | AU$14.54 Million | 30.7% |
| Goodwill | AU$10.02 Million | 21.1% |
Asset Composition Trend (2018–2024)
This chart illustrates how Microba Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MAP company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Microba Life Sciences Ltd's current assets represent 40.1% of total assets in 2024, a decrease from 82.2% in 2018.
- Cash Position: Cash and equivalents constituted 24.8% of total assets in 2024, down from 78.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 1.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 30.7% of total assets.
Microba Life Sciences Ltd Competitors by Total Assets
Key competitors of Microba Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$3.08 Billion |
|
SCOPE FLUIDICS SA ZY-10
F:S84
|
Germany | €195.94 Million |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
Microba Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.73 | 2.17 | 4.84 |
| Quick Ratio | 1.51 | 1.96 | 4.68 |
| Cash Ratio | 0.53 | 1.23 | 0.00 |
| Working Capital | AU$6.80 Million | AU$12.08 Million | AU$12.87 Million |
Microba Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Microba Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | -18.3% |
| Total Assets | AU$47.44 Million |
| Market Capitalization | $30.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Microba Life Sciences Ltd's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Microba Life Sciences Ltd's assets decreased by 18.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual total assets of Microba Life Sciences Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$47.44 Million ≈ $33.56 Million |
-18.27% |
| 2023-12-31 | AU$58.04 Million ≈ $41.07 Million |
+23.61% |
| 2022-12-31 | AU$46.95 Million ≈ $33.22 Million |
+18.93% |
| 2021-12-31 | AU$39.48 Million ≈ $27.93 Million |
+113.54% |
| 2020-12-31 | AU$18.49 Million ≈ $13.08 Million |
+71.06% |
| 2019-12-31 | AU$10.81 Million ≈ $7.65 Million |
-22.75% |
| 2018-12-31 | AU$13.99 Million ≈ $9.90 Million |
-- |
About Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more